Investment Rating - The report maintains a "Buy" rating for Ctrip and Mxue Group, while upgrading Mxue Group's rating from "Hold" to "Buy" [2][8]. Core Insights - Ctrip's Q2 2025 revenue grew by 16% year-on-year to 14.9 billion yuan, with a non-GAAP operating profit of 4.7 billion yuan and a non-GAAP operating margin of 31%, exceeding expectations due to lower marketing expenses [2][7]. - Mxue Group's H1 2025 revenue reached 14.9 billion yuan, a 39% increase year-on-year, with net profit of 2.7 billion yuan, up 44%, driven by higher-than-expected store openings [2][8]. - Gu Ming's H1 2025 revenue was 5.7 billion yuan, a 41% year-on-year increase, with adjusted core profit of 1.1 billion yuan, up 49%, attributed to higher store count and single-store revenue [3][9]. Summary by Sections Ctrip - Q2 2025 revenue increased by 16% to 14.9 billion yuan, with accommodation booking revenue up 21%, transportation revenue up 11%, and group travel revenue up 5% [2][7]. - International OTA platform bookings grew over 60% year-on-year, with inbound tourism bookings more than doubling [2][7]. - The company has fully utilized its $400 million share buyback authorization and approved a new buyback plan of up to $5 billion [2][7]. Mxue Group - H1 2025 revenue was 14.9 billion yuan, a 39% increase, with net profit of 2.7 billion yuan, up 44% [2][8]. - The company is expanding in Southeast Asia, with daily sales growth in Indonesia and Vietnam, and plans for new stores in the U.S. and Latin America [2][8]. - The Lucky Coffee brand complements Mxue's offerings, focusing on freshly ground coffee, enhancing supply chain advantages [2][8]. Gu Ming - H1 2025 revenue reached 5.7 billion yuan, a 41% increase, with adjusted core profit of 1.1 billion yuan, up 49% [3][9]. - The company added 1,265 new stores, bringing the total to 11,179, with a significant increase in stores in lower-tier cities [3][9]. - The average daily GMV per store grew by 21% to 7,600 yuan, benefiting from substantial takeout subsidies [3][9]. Domestic Pharmaceutical Companies - Xinda Biologics reported H1 2025 revenue of 5.953 billion yuan, a 50.6% increase, with net profit turning positive at 834 million yuan [4][13]. - Kangfang Biologics achieved H1 2025 revenue of 1.472 billion yuan, a 37.8% increase, but reported a net loss of 588 million yuan [4][13]. - Rongchang Biologics reported H1 2025 revenue of 1.092 billion yuan, a 47.6% increase, with a reduced net loss of 450 million yuan [4][13]. Overseas Pharmaceutical Companies - Eli Lilly's GLP-1 obesity drug trial showed significant weight loss results, with the 36mg group achieving a 10.5% average weight reduction [5][16]. - BioArctic partnered with Novartis to develop a new CNS drug, receiving an upfront payment of $30 million [5][16]. - Regeneron announced positive results for its MG drug in a Phase III trial, achieving key endpoints [5][16].